The overarching question imparting urgency to this exploration is: Can U.S.-Russian contention in cyberspace cause the two nuclear superpowers to stumble into war? In considering this question we were constantly reminded of recent comments by a prominent U.S. arms control expert: At least as dangerous as the risk of an actual cyberattack, he observed, is cyber operations’ “blurring of the line between peace and war.” Or, as Nye wrote, “in the cyber realm, the difference between a weapon and a non-weapon may come down to a single line of code, or simply the intent of a computer program’s user.”
Dr. Rajeev Venkayya
Dr. Venkayya is the CEO of Aerium Therapeutics, a clinical-stage company dedicated to epidemic and pandemic preparedness through the development of antibodies and antivirals against SARS-CoV-2 and other infectious diseases. He is the former President of the Global Vaccine Business Unit at Takeda Pharmaceuticals, where he built and led a vertically integrated global business developing vaccines for dengue (recently licensed in Brazil, Europe and Indonesia), as well as norovirus, Zika and pandemic threats. Dr. Venkayya serves as an independent member of the board of the Coalition for Epidemic Preparedness Innovations (CEPI) and the International AIDS Vaccine Initiative (IAVI). He was previously Special Assistant to the President for Biodefense at the White House, where he was the principal author of the National Strategy for Pandemic Influenza, and prior to that a White House Fellow. He previously served as Director of Vaccine Delivery at the Bill & Melinda Gates Foundation and on the board of Gavi, the Vaccine Alliance. He trained and served on the faculty in Pulmonary & Critical Care Medicine at UCSF, and in Internal Medicine at the University of Michigan, including as Chief Medical Resident. He received his M.D. from the Northeastern Ohio Universities College of Medicine. He is a member of the Council on Foreign Relations.